Forty-two patients (29 newly diagnosed) with high grade gliomas (n = 37), medulloblastoma (n = 2) or nonbiopsied tumors (n = 3) with supratentorial (n = 24), brain stem (n = 11), posterior fossa (n = 5) or spinal (n = 2) location were eligible for this study with adequate organ function and no bone marrow tumor infiltration. Median patient age was 12.2 years (range, 0.7-46.8). A total of 600 mg/m 2 BCNU, 900 mg/m 2 thiotepa and 1500 or 750 mg/m 2 etoposide (VP-16) was administered followed by autologous bone marrow reinfusion (ABMR). Twenty-one newly diagnosed patients received local irradiation (RT) post ABMR. Nine early deaths were observed (21%), as well as one secondary graft failure. Half of the patients aged 18 years or older experienced toxic deaths, whereas only 15% of patients younger than 18 years experienced toxic death (P = 0.05). Of 25 evaluable newly diagnosed patients, 20% achieved complete remission (CR) and 4% partial remission (PR), while 28% remained in continuing complete remission (CCR) and 44% remained with stable disease prior to RT. Of eight evaluable patients with recurrent disease, one achieved CR and two PR, while one remained in CCR and four with stable disease for 1 to 110.2 months. Overall survival was 36%, 24% and 17% at 1, 2 and 3 years following ABMR, with three newly diagnosed patients and one patient treated for recurrent disease being alive, without disease progression 64.4, 67.0, 86.3 and 110.2 months after ABMR, respectively. The combination of high-dose BCNU/ thiotepa/VP-16 has substantial toxicity but definite activity for high risk CNS tumors. Similar protocols with lower toxicity merit further evaluation in both 
Durable event-free survival is expected for most patients with low grade CNS tumors, such as low grade gliomas, but the majority of patients with high grade lesions, such as high grade gliomas and primitive neuroectodermal tumors, fare substantially worse. By applying multimodality therapies, including conventional-dose chemotherapy, progress has been made. Once a recurrence develops, patients succumb soon thereafter. [1] [2] [3] [4] [5] Chemotherapy alone can achieve objective tumor shrinkage and when combined with adequate surgery and irradiation can prolong patient survival. [5] [6] [7] New approaches are being explored, including the use of high-dose chemotherapy. 3, 4, 8 In contrast to antimetabolites where a plateau is observed in the tumor-response curve, the tumor response to alkylating agents appears to be linear or logarithmic. 9 Additionally, by increasing the administered drug dose, higher cerebrospinal fluid and actual tumor drug concentrations have been documented. [10] [11] [12] Since hematopoietic toxicity can be irreversible or very prolonged when applying 'megadose' chemotherapy, infusion of autologous hematopoietic stem cells can restore hematopoiesis in a timely manner. 9 Carmustine (BCNU) and other nitrosoureas have been used to treat primary CNS malignancies. Thiotepa and etoposide (VP-16) have shown excellent and adequate CNS penetration [13] [14] [15] and have produced responses when given at conventional doses. 12, [16] [17] [18] The thiotepa/VP-16 combination appeared promising in the autologous bone marrow rescue (ABMR) setting for patients with recurrent CNS tumors. 8 The current study represents an attempt to intensify the thiotepa/VP-16 combination with the addition of BCNU and extend its use to newly diagnosed patients. This strat-egy, although associated with significant toxicity among older, heavily pretreated patients, demonstrated long-term survival even in one patient with a recurrent tumor.
Patients and methods

Patients
From September 1988 to October 1993, 42 adult and pediatric patients with high risk newly diagnosed malignant gliomas (high grade lesion; large residual volume; inoperable or brain stem location; CNS dissemination) or recurrent malignant brain tumors were enrolled on this protocol. Patients were required to have good nutritional status, be ambulatory with or without assistance and have adequate hepatic and renal function (serum bilirubin Ͻ2 mg/dl, creatinine clearance Ͼ50 ml/min/1.73 m 2 ) and have no evidence of bone marrow contamination by the tumor. The presence of stable neurologic deficits, excluding impaired gag reflex, was acceptable for study entry. Forty-two patients (23 males) were entered in this limited institution study, involving 10 academic oncology centers in the US, UK and Australia. Median age at ABMR was 12.2 years, range 0.7-46.8 years. None of the patients had evidence of malignant disease outside the CNS.
Patient and treatment characteristics are summarized in Tables 1 and 2 . The majority of patients had glial tumors. Of the newly diagnosed patients eight had brain stem tumors (five with glioblastoma multiforme (GBM), one with anaplastic astrocytoma (AA) and two with unknown pathology (NK)); two patients had spinal tumors (GBM); 12 patients had hemispheric tumors (11 GBM, one AA); four had midline supratentorial tumors (GBM) and three had posterior fossa tumors (GBM). Of the patients treated after recurrence, three had brain stem tumors (one GBM, one AA, one NK); six patients had hemispheric tumors (one AA, three GBM, one gliosarcoma, one anaplastic oligoastrocytoma); two had midline supratentorial tumors (one AA, one anaplastic oligoastrocytoma) and two had posterior fossa tumors (both with medulloblastoma). Tumor pathology was reviewed at the treating institution.
Newly diagnosed patients: An effort was made to attain a state of minimal residual tumor prior to enrollment on to the protocol. Of the newly diagnosed patients, 24 had one surgery (radical resection: eight patients, less than radical resection: 11 patients, biopsy: five patients) and one patient had biopsy followed by radical resection. Due to tumor location within the brain stem, four patients did not have any surgical procedure initially, the diagnosis of malignant CNS tumor being based upon radiographic appearance of the tumor. At ABMR, nine patients had a radiographically estimated widest residual tumor diameter of less than 1.5 cm. Two newly diagnosed patients proceeded to ABMR after primary tumor biopsy and radiographically stable disease following involved field irradiation to 55.8 and 54 Gy, the interval of diagnosis to ABMR being 2.2 and 4.4 months, respectively. Most patients were weaned off steroids prior to ABMR. For all 29 newly diagnosed patients, median time from day of diagnosis to day of ABMR was 1.2 months (range, 0.5-4.4 months).
Recurrent disease patients:
Thirteen patients were treated with ABMR after one to four (median two) tumor recurrences. All patients with recurrent tumors had previously received at least two of the following treatment modalities: surgery, chemotherapy or irradiation. Twelve patients underwent one to three (median two) surgical procedures, but gross total resection was achieved at some point during their course in only three patients. Twelve patients had received involved field (nine patients) or craniospinal irradiation (three patients), with conventional fractionation or hyperfractionated (three patients) irradiation, to a median of 54 Gy (range, 45-72 Gy). Twelve patients had received one to five (median one) chemotherapeutic regimens. Chemotherapy had included platinum compounds (11 patients), nitrosoureas (seven patients) and ifosfamide/cyclophosphamide (three patients). In summary, 10 patients received surgery, irradiation and chemotherapy, one received surgery and irradiation, one received surgery and chemotherapy and one received irradiation and chemotherapy. Only two patients had an estimated widest residual tumor diameter of less than 1.5 cm at ABMR. Median time from day of initial diagnosis to day of ABMR was 18.5 months (range, 6.6-68.2 months) and the time of the most recent relapse to ABMR was 2.0 months (range, 0.5-7.9 months).
Of note, two patients developed primary brain tumors Table 2 ), a 9.6-year-old male, was previously diagnosed with acute lymphocytic leukemia (ALL) and was treated with chemotherapy and cranial irradiation, as well as allogeneic bone marrow transplantation for bone marrow relapse. He developed glioblastoma multiforme while free of detectable ALL. The patient proceeded to BMR with bone marrow (BM) support from his brother who had donated BM for him 4 years earlier. The patient was fully engrafted from the brother and proceeded to the second BM transplant after surgery alone. The second (No. 26, Table 2 ), a 13.4-yearold male, developed glioblastoma multiforme 8 years after he received 54 Gy craniospinal radiation for CNS medulloblastoma. A third patient (No. 23, Table 2 ) was treated for a GBM, developing as a part of an inherited, cancer-related syndrome (Turcot's syndrome 19 ). A number of patients have been included in previous publications. Specifically, the patients referred to in Table 2 with the number 19, 29, 32, 33, 37, 20 3, 7, 8, 12, 13, 15, 30, 33, 21 19, 26 22 and 37. 23 Patient treatment was specified by protocols previously reviewed and approved by the Institutional Review Board of the treating institutions. Informed consent was obtained from all patients or their guardians.
ABMR procedure
Bone marrow was harvested at diagnosis or as soon as patients were considered for the protocol. No purging was applied and BM processing followed the individual institution's protocol. 
Chemotherapy
Supportive care
Platelet counts were to be maintained above 50 000/mm 3 , if possible, to minimize the risk of intracranial (intratumoral) hemorrhage. Hemoglobin was to be maintained above 8.0 g/dl. Infection prophylaxis and treatment were applied according to standard practices and institutional protocols. Hematopoietic growth factors were utilized at physician discretion; nine patients received G-CSF and two patients received GM-CSF.
Post-ABMR irradiation
According to the protocol, all newly diagnosed patients were to receive local irradiation following ABMR. Twenty patients received local irradiation and one patient received craniospinal irradiation at a median dose of 59.4 Gy (range, 54.4-78 Gy), starting on day ϩ42 (range, ϩ30-ϩ60) and ending on day ϩ90 (range, ϩ83-ϩ104).
Evaluation of response
Prior to ABMR, extent of disease was evaluated with physical examination, cerebrospinal fluid analysis when indicated and safe to perform, bone marrow aspirate and biopsy and imaging with computerized tomography (CT), magnetic resonance imaging (MRI) or both. Patients were to be imaged again at days ϩ28, ϩ60 and at 2 month intervals thereafter and according to clinical indications. Response was the radiographically measured change in tumor size (two dimensional), within 2 months following ABMR. Imaging studies evaluating response and disease progression were reviewed at MSKCC Complete response (CR) was defined as no detectable tumor state achieved after ABMR. Continuing complete response (CCR) was defined as continuation of no evidence of disease state that had been achieved with treatment modalities prior to ABMR. Partial response (PR) was defined as greater than 50% reduction in tumor size by imaging and stable disease (SD) was defined as less than 50% reduction in tumor size and without evidence of progressive disease (PD Ͼ25% increase in tumor size).
Toxicity criteria
Toxicity grade was assigned according to the Children Cancer Group criteria. Significant (grade III and IV) toxicities were analyzed and reported.
Statistical evaluation
Event-free survival (EFS) was assessed from the date of bone marrow rescue following myeloablative therapy to the date of disease progression or death (whichever came first) with censoring on the date of most recent contact. Overall survival (OS) was assessed from the date of bone marrow rescue to death with censoring on the date of most recent contact.
Distributions of EFS and OS were estimated using the method of Kaplan and Meier. 24 Differences in survival among patient groups were evaluated with both the logrank and the Wilcoxon tests. 25, 26 Toxic death rate among patient groups was analyzed with the two-tailed Fisher's exact test.
Results
Early mortality
Nine deaths were observed (21%) within the first 60 days post transplantation, occurring 13-49 days (median, 29 days) after BM reinfusion. A significantly greater proportion (four of eight, or 50%) of patients aged 18 years or older experienced a toxic death than did patients who were younger than 18 (five of 34, or 15%) (P = 0.05). The proportion of toxic deaths was somewhat higher among patients treated for recurrent disease (five of 13, or 39%) than newly diagnosed patients (four of 29, or 14%), although this difference was not statistically significant (P = 0.11). Details on patient and treatment characteristics are given in 
Engraftment
The median bone marrow nucleated cell dose administered to recurrent and newly diagnosed patients on day zero was 2.0 ϫ 10 8 cells/kg (range, 1.1-3.1 ϫ 10 8 cells/kg) and 2.2 ϫ 10 8 cells/kg (range, 0.5-6.6 ϫ 10 8 cells/kg), respectively. All evaluable recurrent and newly diagnosed patients had documented myeloid engraftment, achieving an absolute neutrophil count (ANC) of 500 cells/l for 3 consecutive days at a median of 17 days after BM infusion (range, 13-24 days) and 13 days (range, 8-33 days), respectively. Growth factors, granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor, were administered to nine and two patients, respectively, early in the post-transplant period, according to the routine of their treating institution. Untransfused platelet counts of 50 000/l were reached at a median of 27 days (range, 16-510) and 30 days (range, 22-41) for newly diagnosed and recurrent patients, respectively. Only two patients had delayed platelet recovery, on days 103 and 510 post ABMR, but they had platelet counts of more than 20 000/l and no bleeding complications.
One newly diagnosed patient (No. 26) who received 2.1 ϫ 10 8 nucleated cells/kg and achieved myeloid engraftment 14 days following BM infusion, never exhibited platelet engraftment. He then developed decreasing ANC to less than 500 cells/l (secondary graft failure), requiring growth factor support that did not ameliorate the neutropenia durably until day ϩ270 when he succumbed due to tumor progression.
Non-lethal protocol toxicity
Hematologic toxicity: All patients suffered predictable grade IV pancytopenia, requiring blood product support. All but one patient developed febrile episodes while neutropenic.
Non-hematologic toxicity:
Non-lethal, regimen-related toxicity was evaluated in the remaining 33 patients.
Dermatitis/Mucositis: Eleven patients exhibited grade III toxicity to the skin, four and 24 patients developed grade III and IV stomatitis, respectively, necessitating elective intubation in three patients, all during the first 56 days following ABMR.
Liver/GI: Two patients had evidence of veno-occlusive disease of the liver and five, seven and nine patients developed elevated SGPT, SGOT and total bilirubin (zero, one and four patients grade IV, respectively), all during the first 56 days after ABMR. Seven patients had elevated
Bone Marrow Transplantation serum glucose (three patients grade IV), one of which persisted. Seven and one patients developed grade III and IV abdominal pain, while seven and one patients had grade III and IV diarrhea, respectively. Renal/Cardiovascular: Seven patients developed elevated (four patients grade IV) serum creatinine, blood urea nitrogen (BUN) or both, but none persisted beyond day ϩ56. One patient exhibited grade IV elevation of diastolic blood pressure.
Lung: Pulmonary toxicity was significant and possibly related to the nitrosurea treatment. Significant respiratory complications were the initial events precipitating the multiorgan system failure in the majority of the patients who eventually died early in the post-transplant period. At least two other patients exhibited clinical evidence of impaired lung function, as documented by pulmonary function test. Unfortunately, the severity of the neurologic impairment and the short event-free survival did not allow for a full quantification of the respiratory parameters.
Hemostasis: A significant hemorrhagic episode (intracranial hemorrhage) occurred in only one patient (No. 10). Another patient had grade III elevation of prothrombin time but no patient had an elevated partial thromboplastin time.
Electrolytes: Electrolyte abnormalities were as follows: sodium: one patient grade IV; potassium: three patients (I grade IV); calcium: four patients (two grade IV), all within 56 days post transplant.
Neurologic toxicity: Fifteen patients experienced 22 episodes of neurotoxicity. Ten events occurred in six patients prior to marrow reconstitution. In this interval, neurotoxicity consisted of seizures (n = 5), encephalopathy with hallucinations (n = 3) and one episode each of intraparenchymal hemorrhage and spinal myoclonus. Between days 0 and 50 following marrow infusion, neurotoxicity consisted of seizures (n = 5), encephalopathy without hallucinations (n = 2), headache (n = 1) and hemiparesis (n = 1) in seven patients. No events were observed during days ϩ50 to ϩ100 following marrow infusion. After day ϩ100, two patients experienced three events, including one case of transient paresis not related to tumor progression and one case where headache and ataxia were the first signs of tumor progression. Reversible neurotoxicity (17 of 22 events) was associated with metabolic derangements or drug intoxications. Irreversible neurotoxicity was commonly, but not exclusively, an early indication of progressive disease. Neurotoxicity was not significantly related to sex, prior irradiation, prior chemotherapy, tumor histology, the use of steroids or anticonvulsants, the presence of a ventriculoperitoneal shunt, subarachnoid metastatic disease or whether the ABMR procedure was done at initial diagnosis or at disease progression.
Infections: While all patients but one developed febrile neutropenic episodes, 11 of 33 patients had 14 infectious episodes documented during the first 56 days post transplant. These included coagulase negative Staphylococcus central venous catheter infection (two), bacterial sepsis involving K. pneumoniae, E. cloacae, S. aureus, S. viridans and a-hemolytic Streptococcus and three K. pneumoniae pneumonias. Two patients had C. albicans isolated from blood and urine and one patient developed herpetic skin infection. One patient was treated for co-trimoxazole sensitive P. carinii pneumonia.
Between days 57 and 100 after ABMR three patients developed four infectious episodes including two Herpes zoster dermatitides, one Pseudomonas central venous line infection and one episode of S. epidermidis septicemia.
Response to therapy
Thirty-three patients were evaluable for response to treatment. Six patients demonstrated CR following ABMR and eight patients remained in CCR for a median of 54.9 months (range, 3.5-86.3) and 20.2 months (range, 4.6-110.2), respectively. Shorter-lived partial response (2.1-6.5 months) was evident in three patients. Fifteen patients remained alive with stable disease for a median of 5.7 months (range, 1.0-64.4). On day ϩ28 imaging, one patient had evidence of disease progression. Of 25 evaluable newly diagnosed patients there were 20% CR, 28% CCR, 4% PR, 4% PD and 44% SD. The response to treatment according to status at ABMR (newly diagnosed or recurrent patient) is summarized in Table 3 .
Event-free survival and overall survival
Overall survival (OS) and event-free survival (EFS) were calculated for all patients registered on this treatment protocol. The four patients who were alive at last follow-up were also event-free; thus EFS differs from OS only by using time to progression (shorter than time to death). OS and EFS were 36% and 33% at 12 months of follow-up and 24% and 21% at 24 months of follow-up, respectively, with median overall survival of 9.5 months (Figure 1 ).
There were no toxic deaths among eight newly diagnosed patients with brain stem tumors. They all experienced disease progression, with median time to progression 11.7 months (range, 2.5-42.9 months) and median survival 14.1 months (range, 7.6-46.0 months).
Of 25 newly diagnosed patients with GBM of all locations there were four toxic deaths and three patients with tumors located in the hemispheres are long-term survivors. For the GBM patient group, median time to progression was 9.2 months (range, 1.0-62.2 months) and Table 3 Response to treatment Response to treatment for 33 evaluable patients. Nine patients who suffered toxic death were rendered inevaluable. CR = complete response; CCR = continuing complete response; PR = partial response; SD = stable disease; PD = progressive disease. Patients treated for recurrent disease fared worse than patients with newly diagnosed disease, with median survivals of 5.0 and 10.7 months (Figure 2 ), respectively. The log-rank test indicated no significant difference between newly diagnosed and recurrent patients (P = 0.12); however, the Wilcoxon test, which places more weight on early survival times, gives a significant result (P = 0.03). The differing results may be a factor of the small size of this data set. The difference may also warrant verification by analysis with longer follow-up. Thus, caution should be used when interpreting the significance of this comparison of survival for newly diagnosed and recurrent patients. Patients 18 years or older had poorer survivals than did patients who were younger (log-rank P = 0.39, Wilcoxon P = 0.06). In this specific patient cohort there was no difference in outcome for brain stem tumor or other tumor locations, (log-rank P = 0.86, Wilcoxon P = 0.63), although no patient with brain stem tumor is a long-term survivor. Having minimal residual disease prior to ABMR did not alter outcome overall (log-rank P = 0.53, Wilcoxon P = 0.61). Three newly diagnosed patients and one treated for recurrent disease, all with GBM located to the hemispheres, are alive without disease progression 64.4, 67.0, 86.3 months and 110.2 months post ABMR, respectively. Their characteristics are detailed in Tables 2 and 3 . Patient No. 27 (Table 2 ) has no progression of the CNS tumor but has developed a second malignancy, an adenocarcinoma of the colon that led to right hemicolectomy 63.6 months following ABMR.
Discussion
High grade gliomas and brain stem tumors carry a dismal prognosis for newly diagnosed patients or patients with recurrence. The combination of surgery, irradiation and chemotherapy at conventional doses produces low response rates and short survival. For patients with recurrence, palliation is the only realistic approach with conventional modalities. 1, 5, 27, 28 It appears rational to apply agents with activity against CNS tumors in higher doses followed by autologous stem cell reinfusion, in an effort to improve response and outcome and overcome major hematological toxicity. 9 BCNU has been used at conventional and high doses as monotherapy. 29 Other agents, like VP-16 and thiotepa have also been used previously as monotherapies at high doses for the treatment of CNS lesions. 11, 12, 14, 15 Previous reports by Finlay et al 8, 20 using high-dose thiotepa and VP-16 with ABMR in CNS tumors indicated that this approach is feasible and active against recurrent tumors. The current paper summarizes the experience of an intensified protocol consisting of high-dose BCNU/thiotepa/VP-16 used in patients with newly diagnosed or recurrent disease.
Of a total of 42 patients, 29 were newly diagnosed with high grade gliomas and 13 were treated at first recurrence or beyond. The toxic mortality of this very high-dose protocol was significant and appears limiting. Non-fatal toxicity was also high, with appreciable pulmonary toxicity. Based on similar experience, a CCG pilot study (CCG 9922) of a comparable protocol including BCNU/thiotepa/VP-16 was closed to patient accrual (unpublished data) because of unacceptable toxicity. In view of the toxicities, complications and overall mortality and morbidity of the BCNU/thiotepa/VP-16 combination, a modified regimen without a nitrosourea, and which incorporates carboplatin in addition to thiotepa and VP-16 has been developed. 21, 23, 30, 31 Toxicity outcome has been improved and progression-free survival appears promising.
The results of the early response rates are important for this cohort of patients with high risk CNS tumors. They indicate that the chemotherapeutic agent combination used is active against high grade gliomas and other nervous system tumors. Among the newly diagnosed patients, two of five patients who achieved CR and one of 11 patients with stable disease remain alive, free of tumor progression for 64. 4 Newly diagnosed patients who achieved CR with ABMT enjoyed longer progression-free survival than did patients entering ABMT in complete CR (CCR). Two of five patients who achieved CR but none of seven patients in CCR have had durable remissions. Demonstration of chemosensitivity to the myeloablative regimen is not only the advantage of minimal residual disease but it might be of value for long-term outcome.
It is important to note that 21 previously unirradiated, newly diagnosed patients received local irradiation early following ABMR. Radiation therapy remains one of the active modalities against CNS malignancies. Although response outcome is ascribed to the BCNU/thiotepa/VP-16 combination used, long-term outcome is attributed to the combination of surgery, high-dose chemotherapy treatment with ABMR support and irradiation that the patients underwent. Post-ABMR radiotherapy has proven feasible in young and older children with newly diagnosed or recurrent disease. 23, 31 Overall, 33% and 21% of all patients were alive without disease progression 12 and 24 months following ABMR, with newly diagnosed patients faring better than patients treated at recurrence. There was no significant difference in survival depending on age at treatment and brain stem or non-brain stem tumor locations. Long-term survivors were observed 64.4-110.2 months following ABMR.
Direct comparison of the results of this study with the results of larger studies including conventionally treated patients is not feasible. 32 The toxicities observed were limiting. As far less toxic ABMR protocols have been developed, 23, 30, 31 evaluating their activity in short-term response and long-term survival is of great interest.
In summary, the high-dose BCNU/thiotepa/VP-16 protocol followed by ABMR demonstrated activity against high grade gliomas and other high risk CNS malignancies. The observed toxicities were significant and limiting. There was a high mortality and morbidity rate and low survival rate, even for newly diagnosed patients, such that further exploration of this specific ABMR regimen is not warranted. However, given the overall high response rate, other less toxic ABMR regimens are being investigated. In view of the unsatisfactory results of conventional modes of treatment, high-dose protocols with stem cell support merit further evaluation in newly diagnosed and patients with recurrent high risk CNS malignancies. Other less toxic ABMR protocols, employing different dosing and schedule or different agents are currently being investigated.
